Lurafic 40 Tablet contains Lurasidone 40 mg, an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar depression. Lurasidone exerts its therapeutic effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors, which helps in modulating neurotransmitter activity implicated in psychotic and mood disorders. This medication is prescribed to alleviate symptoms such as hallucinations, delusions, disorganized thinking, and mood disturbances. It is important to administer Lurafic 40 with food to enhance absorption and ensure optimal plasma concentration. The dosage should be individualized based on clinical response and tolerability, with careful monitoring for adverse effects including extrapyramidal symptoms, metabolic changes, sedation, and potential QT interval prolongation. Regular assessment of metabolic parameters such as blood glucose, lipid profile, and weight is recommended during treatment. Lurasidone is contraindicated in patients with known hypersensitivity to the drug and should be used cautiously in individuals with a history of seizures or cardiovascular disease. Abrupt discontinuation is discouraged to avoid withdrawal symptoms or relapse. Lurafic 40 Tablet should be used under strict medical supervision, with adherence to prescribed dosing to achieve effective management of psychiatric conditions while minimizing risks.